Perioperative versus adjuvant chemotherapy for pancreatic cancer

A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer

medical-cross
Pancreatic cancer
user
All genders
person-wave 18+
world
Recruiting now
More information  

Overview
Principal Investigator: Jakob Elkon, MD

The purpose of this study is to compare the usual treatment approach (surgery followed by chemotherapy) to using chemotherapy followed by surgery and then more chemotherapy

Study details
Inclusion Criteria
  • Age ≥ 18 years
  • Confirmation of resectable disease by real-time central imaging review by the Alliance Imaging Core Lab at IROC Ohio.
  • Confirmation of resectable disease by real-time central imaging review by the Alliance Imaging Core Lab at IROC Ohio.
Exclusion Criteria
  • Prior radiation therapy, chemotherapy, targeted therapy, investigational therapy, or surgery for pancreatic cancer.
  • Pregnant or nursing
  • Comorbid conditions that would prohibit curative-intent pancreatectomy
Study Requirements

This study has 2 study groups. You will be told which group you are in.

  • Group 1: Subjects will get the usual four-drug regimen used to treat this type of cancer, FOLFIRINOX on the first and second day of each 14-day cycle. Subjects will get this drug regimen for 8 cycles, then have the usual surgery to remove the pancreatic cancer, and then get the usual drug regimen for 4 more cycles.
  • Group 2: Subjects will get the usual four-drug regimen used to treat this type of cancer, FOLFIRINOX on the first and second day of each 14-day cycle. Subjects will then have the usual surgery to remove the pancreatic cancer, then get the usual drug regimen for 12 cycles.